Abstracts tagged "Research"

Abstract Number: 2010 • 2019 ACR/ARP Annual Meeting
Individual Functions of Histone-acetyltransferases CBP and p300 in Regulating Autophagy and Proteasomal Degradation in Synovial Fibroblasts
Monika Krošel¹, Marcel Gabathuler ², Matija Tomšič ¹, Oliver Distler ³, Caroline Ospelt ⁴ and Kerstin Klein ⁵, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Schlieren, ³Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁴University Hospital Zürich, Zürich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland., Zürich, Switzerland
Background/Purpose: Tight control of the two major catabolic pathways proteasomal degradation and autophagy is critical for the maintenance of cellular homeostasis and cell survival. Here…
Abstract Number: 1430 • 2018 ACR/ARHP Annual Meeting
Research Priorities for Addressing Mental Health Needs of Pediatric Patients with Rheumatologic Disease
Tamar Rubinstein¹, Lindsay Waqar², Jennifer Woo³, Ekemini Ogbu⁴, W. Blaine Lapin⁵, Lawrence Ng⁶, Erin Treemarcki⁷ and Andrea M. Knight⁸, ¹Pediatric Rheumatology, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of California Los Angeles, Los Angeles, CA, ⁴Pediatrics, Emory University, Atlanta, GA, ⁵Baylor College of Medicine, Houston, TX, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ⁸Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Mental health problems are prevalent in pediatric rheumatology patients. Gaps in knowledge exist regarding the detection, effective treatment, and the impact of mental illness…
Abstract Number: 2391 • 2018 ACR/ARHP Annual Meeting
Methotrexate Polyglutamates As an Evaluation Tool for Appropriate Dosage of Oral Methotrexate Administration in Pediatric Patients
Nami Okamoto¹, Kosuke Shabana², Yasuo Nakagishi³, Kenichi Nishimura⁴, Mao Mizuta⁵, Yuka Okura⁶, Masaki Shimizu⁵, Hiroyuki Wakiguchi⁷, Junko Yasumura⁸ and Masaaki Mori⁹, ¹Pediatrics, Osaka Medical College, Takatsuki, Japan, ²Department of Pediatrics, Osaka Medical College, Takatsuki, Japan, ³Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan, ⁴Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan, ⁶Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Japan, ⁷Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan, ⁸Department of Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan, ⁹Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Since MTX metabolism varies depending on age and dosage, we need to know optimal MTX administration method in children. We performed multi-center prospective study…
Abstract Number: 2866 • 2018 ACR/ARHP Annual Meeting
Biologic Refractory Disease in a Cohort Study of Children and Young People with Juvenile Idiopathic Arthritis from the United Kingdom
Eleanor Heaf¹, Lianne Kearsley-Fleet¹, Rebecca Davies¹, Diederik De Cock², Eileen Baildam³, Michael W. Beresford^3,4, Helen E. Foster⁵, Taunton R. Southwood⁶, Wendy Thomson^7,8 and Kimme L. Hyrich^2,8, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁵Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁶Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁸National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Biologics are a main treatment option for children and young people with juvenile idiopathic arthritis (JIA) who do not respond or are intolerant to…
Abstract Number: 1291 • 2016 ACR/ARHP Annual Meeting
Performance of Magnetic Resonance Imaging and 18fluoride Sodium Positron Emission Tomography with Computed Tomography to Assess Inflammatory and Structural Abnormalities of the Sacroiliac Joint in Axial Spondyloarthritis
ouichka remy¹, Bouderraoui fehd², raynal marie¹, nguyeon Sime willy³, morel olivier⁴, Chary-valckenaere isabelle⁵, Maksymowych walter⁶, lambert robert⁷, olivier pierre⁸ and Damien Loeuille⁹, ¹rheumatology, nancy hospital university center (france), NANCY, France, ²nuclear medecine, nancy hospital university center (france), NANCY, France, ³Department of epidemiology CIC 1433 CHRU Nancy, France, nancy hospital university center (france), NANCY, France, ⁴deprtment of nuclear medecine, nancy hospital university center (france), NANCY, France, ⁵department of rheumatology, nancy hospital university center (france), NANCY, France, ⁶deprtment of rheumatology, alberta university, edmonton, AB, Canada, ⁷department of radiology, university of alberta, edmonton, AB, Canada, ⁸department of nuclear medecine, nancy hospital university center (france), NANCY, France, ⁹Rheumatology, CHRU Nancy, Vandoeuvre les Nancy, France
Background/Purpose: We aimed to assess increased SIJ uptakes on 18-FNa (an osteoblastic tracer) PET/CT and to compare with MRI SIJ assessments for inflammation and structural…
Abstract Number: 943 • 2015 ACR/ARHP Annual Meeting
Development of an Internationally Agreed Minimal Dataset for Juvenile Dermatomyositis (JDM) for Clinical and Research Use
Liza J. McCann¹, Lucy R Wedderburn², Clarissa Pilkington³, Adam M. Huber⁴, Angelo Ravelli⁵, Jamie Kirkham⁶, Paula Williamson⁶ and Michael W. Beresford⁷, ¹Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, ³Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁴Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁵Pediatria-II, IRCCS G. Gaslini and University of Genova, Genova, Italy, ⁶Department of Biostatistics, University of Liverpool, MRC North West Hub for Trials Methodology Research, Liverpool, United Kingdom, ⁷Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare disease. International collaboration is essential for scrutiny of sufficient patient numbers. We aim to develop a core set…
Abstract Number: 1484 • 2014 ACR/ARHP Annual Meeting
Discovery of ARN-4079 – a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis
Hariprasad Vankayalapati¹, Venkatakrishnareddy Yerramreddy¹, Philip Bendele², Alison Bendele³, Rueban Jacob Anicattu Issac⁴, Ram Sudheer Adluri⁵, Philip LoGrasso⁶ and Joel M. Kremer⁷, ¹Early Discovery and Medicinal Chemistry, Arrien Pharmaceuticals, Salt Lake City, UT, ²Principal Investigator CIA models, Bolder BioPATH, Inc., Boulder, CO, ³Pathologist, Bolder BioPATH Inc., Boulder, CO, ⁴Biology, GVK Biosciences Private Limited., Hyderabad, India, ⁵GVK Biosciences Private Limited., Hyderabad, India, ⁶Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, ⁷Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: The Non-receptor tyrosine kinases, JAK3 and ITK are key regulators of cytokine pathways and are important clinically validated targets, which offer the potential for…
Abstract Number: 1151 • 2014 ACR/ARHP Annual Meeting
Barriers and Facilitators of a Career in Research Among Rheumatologists in the United States
Alexis Ogdie¹, Sheila Angeles-Han², Una Makris³, Amanda Nelson⁴, Ami Shah⁵, Yihui Jiang⁶, J. Michelle Kahlenberg⁷, Eyal Muscal⁸, Flavia V. Castelino⁹, Amit Golding¹⁰ and Alfred Kim¹¹, ¹Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Pediatrics, Emory University School of Medicine, Atlanta, GA, ³Rheumatology, Dallas VA Medical Ctr, Dallas, TX, ⁴5) Division of Rheumatology, Allergy, and Immunology and Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Division of Rheumatology, John Hopkins University, Baltimore, MD, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁷Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁸Rheumatology, Texas Children's Hospital, Houston, TX, ⁹Rheumatology, Massachusetts General Hospital, Boston, MA, ¹⁰Medicine/Rheumatology and Clinical Immunology, Baltimore VA and University of Maryland School of Medicine, Baltimore, MD, ¹¹Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO
Background/Purpose: Development of young rheumatology investigators is critical to the future of rheumatology. Beyond funding, the specific barriers to maintaining a career in rheumatology research…
Abstract Number: 104 • 2014 ACR/ARHP Annual Meeting
Reasons for Leaving an Academic Career in Research Among Rheumatologists in the United States
Alexis Ogdie¹, Ami Shah², Una Makris³, Alfred Kim⁴, Sheila Angeles-Han⁵, Amit Golding⁶, J. Michelle Kahlenberg⁷, Eyal Muscal⁸, Flavia V. Castelino⁹ and Amanda Nelson¹⁰, ¹Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, John Hopkins University, Baltimore, MD, ³Rheumatology, Dallas VA Medical Ctr, Dallas, TX, ⁴Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, ⁵Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁶Medicine/Rheumatology and Clinical Immunology, Baltimore VA and University of Maryland School of Medicine, Baltimore, MD, ⁷Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁸Rheumatology, Texas Children's Hospital, Houston, TX, ⁹Rheumatology, Massachusetts General Hospital, Boston, MA, ¹⁰5) Division of Rheumatology, Allergy, and Immunology and Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Reasons for leaving an academic career in research among rheumatologistsBackground/Purpose: Retention of academic rheumatologists in research careers is increasingly challenging in the current funding environment. …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].